Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

NCT00201695 ↗

Phase 2 Completed 12 enrolled Ohio State University Comprehensive Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

This study will assess the ability of Doxorubicin, Vincristine and Dexamethasone plus arsenic trioxide to achieve an overall response rate of greater than 60%.

Timeline

Start: 2004-07
Primary completion: 2006-09
Completion: 2008-08

Publications

Results Hofmeister CC, Jansak B, Denlinger N, Kraut EH, Benson DM, Farag SS. Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leuk Res. 2008 Aug;32(8):1295-8. doi: 10.1016/j.leukres.2007.10.020. Epub 2007 Dec 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexamethasone	Small molecule	40 mg	Oral
Subject	Doxorubicin	Other / unclassified	40 mg/m2	Intravenous
Subject	Vincristine	Small molecule	1.4 mg/m2	Intravenous
Subject	arsenic trioxide	Small molecule	0.25 mg/kg	Intravenous

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications